Monoclonal antibodies (mAbs) are highly-specific and bind to only one epitope, making them invaluable tools for a wide range of applications in biotechnology, cell biology, cancer research, genomics, pharmacology, and more. They are also a key component for diagnostic, prophylactic, and therapeutic products. This article discusses the development, history, and advantages of different mAb production techniques.

Hybridoma custom monoclonal antibodies for targetted research is the primary method for generating monoclonal antibodies, which involves fusing antibody-producing B cells with immortal myeloma cells to produce hybridomas that continuously produce high-yield mAbs. Other mAb production methods include electrofusion; phage, yeast, bacterial, and mammalian display systems; recombinant antibody synthesis; single B cell technology; and transgenic animal platforms.

Recombinant Protein Services: Accelerating Modern Research and Drug Discovery

Biohit’s extensive catalog of custom monoclonal antibodies includes both rat and human mAbs, providing researchers with the optimal solution for their targetted research applications. Our mAbs are tested for cross-reactivity, batch-to-batch consistency, and performance in a wide range of experimental conditions, including ELISA, WB, IHC, flow cytometry, cell-based assays, and affinity ranking. Additionally, many of our mAbs are compatible with paraffin-embedded sections, though compatibility varies by antibody.

Our human mAbs target the extracellular matrix (ECM), an essential structural framework that provides support to surrounding cells and controls a number of cellular functions, including cell adhesion, migration, and gene expression. These ECM-specific mAbs are used in studies of fibrosis, cancer, tissue repair, and vascularization. Additionally, our mAbs for integrins are useful in the study of ECM components such as fibronectin, tenascin, and laminin.